NCT02113878 - Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2014

Primary Completion Date

December 6, 2019

Study Completion Date

January 1, 2022

Conditions

Carcinoma, Squamous Cell of Head and NeckHPV Positive Oropharyngeal Squamous Cell CarcinomaHypopharyngeal CancerEarly Invasive Cervical Squamous Cell CarcinomaCarcinoma of LarynxCancer of Nasopharynx

Interventions

DRUG

BKM120

BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.

DRUG

Cisplatin

Cisplatin is a chemotherapy drug

RADIATION

Intensity-modulated radiotherapy (IMRT)

IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston